After initial breast cancer treatment, pharmacists can help patients navigate ongoing endocrine therapy, manage persistent adverse effects, and address medication concerns that affect long-term care.
|Articles|July 6, 2022
Daily OTC Pearl: Legatrin PM
Author(s)Saro Arakelians, PharmD
Legatrin PM is intended for relief of lower body pain.
Advertisement
OTC/Lifestyle Pearl of the Day: Legatrin PM
Indication: Legatrin PM is intended for relief of lower body pain.
Insight:
- Active Ingredients (per Caplet): Acetaminophen (500 mg), diphenhydramine HCl (50 mg). Inactive ingredients: croscarmellose sodium, D&C red No. 27 lake, dicalcium phosphate, FD&C blue no. 1 lake, FD&C red no. 40 lake, FD&C yellow no. 6 lake, hydroxypropyl methylcellulose, magnesium silicate, magnesium stearate, microcrystalline cellulose, mineral oil, polyethylene glycol, stearic acid, titanium dioxide.
- Directions: Adults and children 12 years of age and older: 1 caplet at bedtime or as directed by a physician. Do not give to children under the age of 12 years unless directed by your physician. Do not exceed recommended dosage. Store at room temperature.
- Consult a physician before use if you have glaucoma; breathing problems such as asthma, emphysema, chronic bronchitis or pulmonary disease; trouble urinating due to an enlarged prostate gland.
Advertisement
Related to this article
Parminder K. Judge, PhD, explains why eGFR and electrolytes should be monitored when diuretics are added to reach intensive BP targets in patients with CKD
The project maps how flu and HIV proteins enter cells, with the aim of developing longer-lasting vaccines.
Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
Pharmacy teams can prevent early discontinuation by setting clear expectations for when—and how—a medication's benefit will become apparent.
The once-daily device, bioequivalent to the existing prefilled syringe, gives adults with AChR antibody-positive generalized MG a second self-injection option.
A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Finerenone Expands MRA Options as Pharmacists Address Underrecognized HFpEF
2
Diuretics, eGFR, and Intensive BP Lowering in CKD: What to Watch
3
Finerenone in Heart Failure: Evidence and Practice a Year Later
4
Researchers Target Viral Fusion for Universal Flu, HIV Vaccines
5